T cell responses against mutant ras: a basis for novel cancer vaccines.
Gaudernack
G
G
Department of Immunology, Norwegian Radium Hospital, Oslo, Norway.
D017951:Antigen Presentation; D015704:CD4 Antigens / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D015689:Oncogene Protein p21(ras) / Q000276:immunology*; D010455:Peptides / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology
D015704:CD4 Antigens; D019496:Cancer Vaccines; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D010455:Peptides; D015689:Oncogene Protein p21(ras)